Corporate ActionJun 2, 2026, 04:02 PM
NRx Pharmaceuticals Plans Underwritten Public Offering
AI Summary
NRx Pharmaceuticals, Inc. announced its intention to offer shares of its common stock in an underwritten public offering. The company expects to grant the underwriter a 30-day option to purchase up to an additional 15% of the shares sold. Proceeds from the offering are intended for working capital and general corporate purposes to support growth. The offering is subject to market and other conditions, with no assurance as to its completion, size, or terms.
Key Highlights
- NRx Pharmaceuticals announced an underwritten public offering of common stock.
- Underwriter has a 30-day option to purchase up to an additional 15% of shares.
- Net proceeds will be used for working capital and general corporate purposes.
- BTIG, LLC is the lead bookrunner; Lucid Capital Markets, LLC is joint bookrunning manager.
- The offering is subject to market and other conditions.
- Shares will be offered under an effective shelf registration statement on Form S-3.
Price Impact
More from NRXP